Premium
The future of recombinant coagulation factors
Author(s) -
Saenko E. L.,
Ananyeva N. M.,
Shima M.,
Hauser C. A. E.,
Pipe S. W.
Publication year - 2003
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1046/j.1538-7836.2003.00196.x
Subject(s) - recombinant dna , coagulation , receptor , reactivity (psychology) , computational biology , antibody , factor ix , chemistry , medicine , immunology , biology , biochemistry , gene , alternative medicine , pathology
Summary. Hemophilias A and B are X chromosome‐linked bleeding disorders, which are mainly treated by repeated infusions of factor (F)VIII or FIX, respectively. In the present review, we specify the limitations in expression of recombinant (r)FVIII and summarize the bioengineering strategies that are currently being explored for constructing novel rFVIII molecules characterized by high efficiency expression and improved functional properties. We present the strategy to prolong FVIII lifetime by disrupting FVIII interaction with its clearance receptors and demonstrate how construction of human‐porcine FVIII hybrid molecules can reduce their reactivity towards inhibitory antibodies. While the progress in improving rFIX is impeded by low recovery rates, the authors are optimistic that the efforts of basic science may ultimately lead to higher efficiency of replacement therapy of both hemophilias A and B.